| Income statement (USD) | FY 2025 ended Nov 30, 2025 | FY 2024 ended Nov 30, 2024 | FY 2023 ended Nov 30, 2023 | FY 2022 ended Nov 30, 2022 | FY 2021 ended Nov 30, 2021 | FY 2020 ended Nov 30, 2020 |
|---|---|---|---|---|---|---|
| Revenue | 83.98M | 54.55M | 76.99M | 38.63M | 29.75M | 17.82M |
| Research and development | 316.90M | 221.63M | 189.15M | 184.50M | 116.43M | 66.49M |
| Operating expenses | 369.65M | 267.58M | 232.05M | 222.49M | 147.64M | 82.80M |
| Operating income | -285.67M | -213.03M | -155.06M | -183.87M | -117.89M | -64.98M |
| EBITDA | -276.93M | -203.71M | -147.53M | -178.52M | -115.10M | -62.80M |
| Income before tax | -263.70M | -193.30M | -143.95M | -180.36M | -117.06M | -63.78M |
| Income tax | 760.0K | 270.0K | 0 | 0 | 131.0K | -20.54M |
| Net income | -264.46M | -193.57M | -143.95M | -180.36M | -117.19M | -43.24M |
| EPS | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | |
| EPS (diluted) | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 |
| Diluted shares | 86.67M | 67.12M | 54.34M | 48.61M | 42.90M | |
| Dividends per share | 0.00 | 0.00 | 0.00 |
From Nurix Therapeutics, Inc.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.